This study has been suspended due to a lack of funding. The protocol will be reconsidered within the next 6-12 months if/as funding becomes available.
Summary
The primary objective of the study is to describe the recovery and survival of pathogen-reduced (PR) red blood cells (RBCs) prepared and stored with the INTERCEPT Blood System for RBCs® (hereafter referred to as INTERCEPT RBCs) in patients with sickle cell disease (SCD) undergoing red cell exchange (RCE) therapy, utilizing flow cytometry for biotin and acridine RBC surface markers.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-27; most recent amendment 2026-04-06.
Status change: Not Yet Recruiting → Withdrawn2026-04-06